Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH

Journal of Lipid Research

Volumn 56, Issue 2, 2015, Pages 277-285

  Ioannou, George N ^a   Van Rooyen, Derrick M ^b   Savard, Christopher ^a   Haigh, W Geoffrey ^a   Yeh, Matthew M ^c   Teoh, Narci C ^b   Farrell, Geoffrey C ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CANBERRA HOSPITAL   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Caspase 1; Crown like structure; Lipotoxicity; Nonalcoholic steatohepatitis

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CRYOPYRIN; EZETIMIBE; FAT DROPLET; HYPOCHOLESTEROLEMIC AGENT; INFLAMMASOME; TUMOR NECROSIS FACTOR ALPHA; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DISSOLUTION; DRUG EFFICACY; FEMALE; KUPFFER CELL; LIPID DIET; LIVER CELL; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OB/OB MOUSE; ANIMAL; DRUG EFFECTS; LIVER; METABOLISM; MUTANT MOUSE STRAIN; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; AZETIDINES; CHOLESTEROL; EZETIMIBE; FEMALE; HEPTANOIC ACIDS; INFLAMMASOMES; KUPFFER CELLS; LIVER; MICE; MICE, MUTANT STRAINS; NON-ALCOHOLIC FATTY LIVER DISEASE; PYRROLES;

EID: 84921905230     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M053785     Document Type: Article

References (41)

1. Matteoni, C. A., Z. M. Younossi, T. Gramlich, N. Boparai, Y. C. Liu, and A. J. McCullough. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116: 1413-1419.
2. Bugianesi, E., N. Leone, E. Vanni, G. Marchesini, F. Brunello, P. Carucci, A. Musso, P. De Paolis, L. Capussotti, M. Salizzoni, et al. 2002. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123: 134-140.
3. Puri, P., R. A. Baillie, M. M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. Sargeant, M. J. Contos, and A. J. Sanyal. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46: 1081-1090.
4. Matsuzawa, N., T. Takamura, S. Kurita, H. Misu, T. Ota, H. Ando, M. Yokoyama, M. Honda, Y. Zen, Y. Nakanuma, et al. 2007. Lipidinduced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 46: 1392-1403.
5. Zheng, S., L. Hoos, J. Cook, G. Tetzloff, H. Davis, Jr ., M. van Heek, and J. J. Hwa. 2008. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 584: 118-124.
6. Van Rooyen, D. M., C. Z. Larter, W. G. Haigh, M. M. Yeh, G. Ioannou, R. Kuver, S. P. Lee, N. C. Teoh, and G. C. Farrell. 2011. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141: 1393-1403, 1403.e1-5.
7. Savard, C., E. V. Tartaglione, R. Kuver, W. G. Haigh, G. C. Farrell, S. Subramanian, A. Chait, M. M. Yeh, L. S. Quinn, and G. N. Ioannou. 2013. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 57: 81-92.
8. Van Rooyen, D. M., L. T. Gan, M. M. Yeh, W. G. Haigh, C. Z. Larter, G. Ioannou, N. C. Teoh, and G. C. Farrell. 2013. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 59: 144-152.
9. Wouters, K., M. van Bilsen, P. J. van Gorp, V. Bieghs, D. Lutjohann, A. Kerksiek, B. Staels, M. H. Hofker, and R. Shiri-Sverdlov. 2010. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 584: 1001-1005.
10. Wouters, K., P. J. van Gorp, V. Bieghs, M. J. Gijbels, H. Duimel, D. Lutjohann, A. Kerksiek, R. van Kruchten, N. Maeda, B. Staels, et al. 2008. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 48: 474-486.
11. Bieghs, V., P. J. Van Gorp, K. Wouters, T. Hendrikx, M. J. Gijbels, M. van Bilsen, J. Bakker, C. J. Binder, D. Lutjohann, B. Staels, et al. 2012. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in nonalcoholic fatty liver disease. PLoS ONE. 7: e30668.
12. Subramanian, S., L. Goodspeed, S. Wang, J. Kim, L. Zeng, G. N. Ioannou, W. G. Haigh, M. M. Yeh, K. V. Kowdley, K. D. O'Brien, et al. 2011. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52: 1626-1635.
13. Itoh, M., T. Suganami, N. Nakagawa, M. Tanaka, Y. Yamamoto, Y. Kamei, S. Terai, I. Sakaida, and Y. Ogawa. 2011. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am. J. Pathol. 179: 2454-2463.
14. Chan, J., F. E. Sharkey, R. S. Kushwaha, J. F. VandeBerg, and J. L. VandeBerg. 2012. Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. Am. J. Physiol. Gastrointest. Liver Physiol. 303: G12-G19.
15. Ioannou, G. N., O. B. Morrow, M. L. Connole, and S. P. Lee. 2009. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology. 50: 175-184.
16. Yoneda, M., K. Fujita, Y. Nozaki, H. Endo, H. Takahashi, K. Hosono, K. Suzuki, H. Mawatari, H. Kirikoshi, M. Inamori, et al. 2010. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol. Res. 40: 566-573.
17. Park, H., T. Shima, K. Yamaguchi, H. Mitsuyoshi, M. Minami, K. Yasui, Y. Itoh, T. Yoshikawa, M. Fukui, G. Hasegawa, et al. 2011. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol. 46: 101-107.
18. Ioannou, G. N., W. G. Haigh, D. Thorning, and C. Savard. 2013. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 54: 1326-1334.
19. Cinti, S., G. Mitchell, G. Barbatelli, I. Murano, E. Ceresi, E. Faloia, S. Wang, M. Fortier, A. S. Greenberg, and M. S. Obin. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46: 2347-2355.
20. Strissel, K. J., Z. Stancheva, H. Miyoshi, J. W. Perfield 2nd, J. DeFuria, Z. Jick, A. S. Greenberg, and M. S. Obin. 2007. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 56: 2910-2918.
21. Duewell, P., H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nunez, M. Schnurr, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 464: 1357-1361.
22. Rajamaki, K., J. Lappalainen, K. Oorni, E. Valimaki, S. Matikainen, P. T. Kovanen, and K. K. Eklund. 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE. 5: e11765.
23. Heydet, D., L. X. Chen, C. Z. Larter, C. Inglis, M. A. Silverman, G. C. Farrell, and M. R. Leroux. 2013. A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev. Neurobiol. 73: 1-13.
24. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, et al. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321.
25. Rudolf, M., and C. A. Curcio. 2009. Esterified cholesterol is highly localized to Bruch's membrane, as revealed by lipid histochemistry in wholemounts of human choroid. J. Histochem. Cytochem. 57: 731-739.
26. Ganz, M., T. Csak, B. Nath, and G. Szabo. 2011. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J. Gastroenterol. 17: 4772-4778.
27. Tabas, I. 2002. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J. Clin. Invest. 110: 905-911.
28. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell. 140: 821-832.
29. Martinon, F., V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 440: 237-241.
30. Hornung, V., F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, and E. Latz. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9: 847-856.
31. Dostert, C., V. Petrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 320: 674-677.
32. Cassel, S. L., S. C. Eisenbarth, S. S. Iyer, J. J. Sadler, O. R. Colegio, L. A. Tephly, A. B. Carter, P. B. Rothman, R. A. Flavell, and F. S. Sutterwala. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. USA. 105: 9035-9040.
33. Hawes, B. E., K. A. O'Neill, X. Yao, J. H. Crona, H. R. Davis, Jr ., M. P. Graziano, and S. W. Altmann. 2007. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs. Mol. Pharmacol. 71: 19-29.
34. Betters, J. L., and L. Yu. 2010. NPC1L1 and cholesterol transport. FEBS Lett. 584: 2740-2747.
35. Athyros, V. G., K. Tziomalos, T. D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, E. D. Pagourelias, E. Theocharidou, A. Karagiannis, D. P. Mikhailidis, et al. 2010. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 376: 1916-1922.
36. Athyros, V. G., D. P. Mikhailidis, T. P. Didangelos, O. I. Giouleme, E. N. Liberopoulos, A. Karagiannis, A. I. Kakafika, K. Tziomalos, A. K. Burroughs, and M. S. Elisaf. 2006. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 22: 873-883.
37. Foster, T., M. J. Budoff, S. Saab, N. Ahmadi, C. Gordon, and A. D. Guerci. 2011. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol. 106: 71-77.
38. Nelson, A., D. M. Torres, A. E. Morgan, C. Fincke, and S. A. Harrison. 2009. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J. Clin. Gastroenterol. 43: 990-994.
39. Chan, D. C., G. F. Watts, S. K. Gan, E. M. Ooi, and P. H. Barrett. 2010. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 33: 1134-1139.
40. Takeshita, Y., T. Takamura, M. Honda, Y. Kita, Y. Zen, K. Kato, H. Misu, T. Ota, M. Nakamura, K. Yamada, et al. 2014. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 57: 878-890.
41. Smith, S. C., Jr ., and S. M. Grundy. 2014. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J. Am. Coll. Cardiol. 64: 601-612.